Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 3-(dibutylamino)propyl 4-aminobenzoate
2. Butacaine Sulfate
3. Butaprobenz
4. Butocain
1. 149-16-6
2. 3-(dibutylamino)propyl 4-aminobenzoate
3. P-aminobenzoyldibutylaminopropanol
4. 1-propanol, 3-(dibutylamino)-, 4-aminobenzoate (ester)
5. 3-(dibutylamino)-1-propanol P-aminobenzoate
6. 3-dibutylaminopropyl P-aminobenzoate
7. 3-(p-aminobenzoxy)-1-di-n-butylaminopropane
8. Butelline
9. Nsc-758632
10. Z84s23cgjj
11. Mls000028619
12. Ncgc00016411-01
13. Cas-149-16-6
14. Smr000058686
15. 1-propanol, 3-(dibutylamino)-, P-aminobenzoate (ester)
16. Dsstox_cid_25300
17. Dsstox_rid_80789
18. Dsstox_gsid_45300
19. 1-propanol, 3-(dibutylamino)-, 1-(4-aminobenzoate)
20. Butacainum
21. Butacaina
22. Butacaine [inn:ban]
23. Butacainum [inn-latin]
24. Butacaina [inn-spanish]
25. Sr-01000003139
26. Einecs 205-734-7
27. Unii-z84s23cgjj
28. Brn 2135378
29. Prestwick_984
30. Spectrum_001562
31. Butacaine [inn]
32. Butacaine [mi]
33. Opera_id_1473
34. Prestwick0_000831
35. Prestwick1_000831
36. Prestwick2_000831
37. Prestwick3_000831
38. Spectrum2_001593
39. Spectrum3_001943
40. Spectrum4_000219
41. Spectrum5_001565
42. Butacaine [vandf]
43. Butacaine [who-dd]
44. Schembl26156
45. Bspbio_000781
46. Bspbio_003543
47. Kbiogr_000857
48. Kbioss_002042
49. Divk1c_000864
50. Spectrum1503914
51. Spbio_001586
52. Spbio_002702
53. Bpbio1_000861
54. Chembl129529
55. Dtxsid3045300
56. Chebi:94820
57. Hms502l06
58. Kbio1_000864
59. Kbio2_002042
60. Kbio2_004610
61. Kbio2_007178
62. Kbio3_002827
63. Ninds_000864
64. Hms1570h03
65. Hms1922k10
66. Hms2093k17
67. Hms2097h03
68. Hms2230j20
69. Hms3371o14
70. Hms3714h03
71. Pharmakon1600-01503914
72. Hy-b1007
73. Zinc1596184
74. Tox21_110428
75. Bdbm50225491
76. Ccg-39371
77. Nsc758632
78. Akos024374899
79. Tox21_110428_1
80. Cs-4504
81. Db11502
82. Nsc 758632
83. Idi1_000864
84. Ncgc00016411-02
85. Ncgc00016411-03
86. Ncgc00016411-04
87. Ncgc00016411-05
88. Ncgc00016411-06
89. Ncgc00016411-07
90. Ncgc00016411-10
91. Ncgc00023714-03
92. Ncgc00023714-04
93. Ncgc00023714-05
94. 3-(dibutylamino)propyl 4-aminobenzoate #
95. (3-di-n-butylaminopropyl)-p-aminobenzoate
96. Sbi-0051856.p002
97. Ab00052382
98. Sw197068-3
99. 1-propanol, 3-(dibutylamino)-, 4-aminobenzoate
100. 1-propanol, 3-(dibutylamino)-, P-aminobenzoate
101. 4-aminobenzoic Acid 3-(dibutylamino)propyl Ester
102. Ab00052382_15
103. Ab00052382_16
104. J-008557
105. J-008559
106. Q5002339
107. Sr-01000003139-2
108. Sr-01000003139-3
109. Brd-k99622919-001-05-7
110. Brd-k99622919-001-15-6
111. 3-(dibutylamino)-1-propanol P-aminobenzoate (ester)
Molecular Weight | 306.4 g/mol |
---|---|
Molecular Formula | C18H30N2O2 |
XLogP3 | 4.5 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 12 |
Exact Mass | 306.230728204 g/mol |
Monoisotopic Mass | 306.230728204 g/mol |
Topological Polar Surface Area | 55.6 Ų |
Heavy Atom Count | 22 |
Formal Charge | 0 |
Complexity | 281 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Anesthetics, Local
Drugs that block nerve conduction when applied locally to nerve tissue in appropriate concentrations. They act on any part of the nervous system and on every type of nerve fiber. In contact with a nerve trunk, these anesthetics can cause both sensory and motor paralysis in the innervated area. Their action is completely reversible. (From Gilman AG, et. al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed) Nearly all local anesthetics act by reducing the tendency of voltage-dependent sodium channels to activate. (See all compounds classified as Anesthetics, Local.)
ABOUT THIS PAGE
A Butacaine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Butacaine, including repackagers and relabelers. The FDA regulates Butacaine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Butacaine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Butacaine supplier is an individual or a company that provides Butacaine active pharmaceutical ingredient (API) or Butacaine finished formulations upon request. The Butacaine suppliers may include Butacaine API manufacturers, exporters, distributors and traders.
Butacaine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Butacaine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Butacaine GMP manufacturer or Butacaine GMP API supplier for your needs.
A Butacaine CoA (Certificate of Analysis) is a formal document that attests to Butacaine's compliance with Butacaine specifications and serves as a tool for batch-level quality control.
Butacaine CoA mostly includes findings from lab analyses of a specific batch. For each Butacaine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Butacaine may be tested according to a variety of international standards, such as European Pharmacopoeia (Butacaine EP), Butacaine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Butacaine USP).
LOOKING FOR A SUPPLIER?